A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard
therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or
ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation
directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or
crizotinib and standard therapy may work better in treating younger patients with
neuroblastoma or ganglioneuroblastoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.